http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009097259-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e9bf1632287417744a3647a57501f8d7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_468ba69b8e2068e9319b9942dcc081b3
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55
filingDate 2009-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ebd4b03f1f1e687c9b556afb4e2b7a1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d65ee2cdb63e422905124b19eee46b71
publicationDate 2009-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2009097259-A3
titleOfInvention Use of ibogamine congeners for treating obesity
abstract The present invention relates to a method of treating obesity in a subject by administering to the subject a compound having the formula (I) wherein n is from 0 to 8; R1 is CH2OH, CH(OH)R5, CH2OR5, CO2R5, C(O)NH2, C(O)NHR5, C(O)NR5R6, C(O)NHNH2, C(O)NHNHR5, C(O)NHNR5R6, C(O)NR5NH2, C(O)NR5NHR6, C(O)NR5NR6R7, C(O)NHNH(C(O)R5), C(O)NHNR5(C(O)R6), C(O)NR5NH(C(O)R6), C(O)NR5NR6(C(O)R7), CN, or C(O)R5; R2 is H, unsubstituted or substituted alkyl, YH, YR8, YR8R9, YR8YR9YR10, YC(O)R8, C(O)YR8, C(O)NH2, C(O)NHR8, C(O)NR8R9, NH2, NHR8, NR8R9, NHC(O)R8, or NR8C(O)R9; R3 and R4 are the same or different and are selected from the group consisting of H, halogens, unsubstituted or substituted alkyl, OH, OR10, NH2, NHR10, NR10R11, NHC(O)R10, or NR10C(O)R11; R5, R6, R7, R8, R9, R10, and R11 are the same or different and are selected from the group consisting of H, unsubstituted alkyl, substituted alkyl, unsubstituted aryl and substituted aryl; R12 is selected from the group consisting of H, unsubstituted alkyl, and substituted alkyl; and Y is O or S; and pharmaceutically acceptable salts thereof.
priorityDate 2008-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003199496-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6211360-B1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226757190
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID100217

Total number of triples: 19.